IMBiologics아이엠바이오로직스
493280 · KOSDAQ · ₩493280 · 아이엠바이오로직스
₩13,160▼ ₩640 (4.64%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Revenue | ₩0 | ₩7.2B |
| Cost of sales | ₩2.7B | ₩4.5B |
| Gross profit | −₩2.7B | ₩2.7B |
| Operating income | −₩2.7B | ₩2.7B |
| Net income | −₩2.1B | ₩3.8B |
| Net income to shareholders | −₩2.1B | ₩3.8B |
Balance sheet
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Total assets | ₩129B | ₩131B |
| Current assets | ₩125B | ₩129B |
| Cash and equivalents | ₩48B | ₩670M |
| Total liabilities | ₩2.5B | ₩3.3B |
| Current liabilities | ₩1.3B | ₩2.5B |
| Borrowings | ₩855M | ₩2.5B |
| Total equity | ₩126B | ₩128B |
| Shareholders' equity | ₩126B | ₩128B |
Cash flow
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Cash from operations | −₩3.5B | ₩5B |
| Capital spending | ₩59M | ₩658M |
| Free cash flow | −₩3.6B | ₩4.4B |
Consolidated where available. Amounts in won.
Also known as: IMBiologics / 아이엠바이오로직스 / 493280 / KRX:493280
Source: KRX statistical information